Fixed-Duration Venetoclax Regimens Match Continuous BTKi in Frontline CLL

The results of the CLL17 trial show that patients with untreated CLL can be offered a time-limited, chemotherapy-free regimen without compromising PFS. According to Dr Othmann Al-Sawaf, this is an essential step toward individualised treatment of patients with CLL.